BRIUMVI Drug Profile
Summary for Tradename: BRIUMVI
| High Confidence Patents: | 0 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for BRIUMVI |
Recent Clinical Trials for BRIUMVI
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| University of Maryland, Baltimore | NA |
| TG Therapeutics, Inc. | NA |
| TG Therapeutics, Inc. | PHASE4 |
Pharmacology for BRIUMVI
| Mechanism of Action | CD20-directed Antibody Interactions |
| Established Pharmacologic Class | CD20-directed Cytolytic Antibody |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for BRIUMVI Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for BRIUMVI Derived from DrugPatentWatch Analysis and Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for BRIUMVI Derived from Patent Text Search
No patents found based on company disclosures
BRIUMVI Market Dynamics and Financial Trajectory: Sales Growth, Competition, Exclusivity and Commercial Outlook
BRIUMVI, TG Therapeutics' ublituximab-xiiy, has become one of the fastest-growing therapies in the multiple sclerosis market since its FDA approval in December 2022. The drug generated approximately $362.6 million in U.S. net product sales in 2023, its first full commercial year, and continued to grow at an annualized rate above $400 million in early 2024. Its commercial position rests on rapid intravenous administration, six-month dosing, a competitive price, and increasing physician familiarity.
The main risks are competition from Roche's OCREVUS, Novartis' KESIMPTA and biosimilar or follow-on anti-CD20 products later in the decade. BRIUMVI's commercial durability also depends on maintaining payer access, expanding infusion-center capacity and converting patients from established anti-CD20 therapies.
What is BRIUMVI and which patients does it treat?
BRIUMVI is an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis in adults. The indication includes clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.
| Attribute | BRIUMVI |
|---|---|
| Active ingredient | Ublituximab-xiiy |
| Sponsor | TG Therapeutics, Inc. |
| FDA approval | Dec. 28, 2022 |
| FDA application | BLA 761238 |
| Therapeutic class | Anti-CD20 monoclonal antibody |
| Administration | Intravenous infusion |
| Maintenance schedule | Every 24 weeks |
| Main market | Relapsing multiple sclerosis |
| Commercial launch | First quarter of 2023 |
| Primary competitors | OCREVUS, KESIMPTA, rituximab, TYSABRI and other high-efficacy MS therapies |
BRIUMVI is designed to deplete CD20-positive B cells. Its glycoengineered Fc region is intended to increase antibody-dependent cellular cytotoxicity. The principal clinical value proposition is a short maintenance infusion administered twice annually after the initial dosing schedule.
How large is the BRIUMVI market opportunity?
The addressable U.S. market is the high-efficacy segment of multiple sclerosis treatment, particularly patients with active relapsing disease who require disease-modifying therapy. The United States has roughly 1 million people living with MS, although the treated relapsing population is materially smaller than the total prevalence population.
Anti-CD20 therapies have reshaped the market because they combine strong efficacy with dosing schedules that are relatively convenient for patients. OCREVUS remains the category leader, while KESIMPTA has expanded the self-administered subcutaneous segment. BRIUMVI competes primarily for patients and physicians who prefer infusion-based treatment but want a shorter administration time than OCREVUS.
BRIUMVI's key commercial advantages are:
- A maintenance infusion every 24 weeks.
- A one-hour maintenance infusion after the initial dosing period.
- A lower list price than OCREVUS.
- Infusion-center administration, which gives providers control over treatment delivery.
- A mechanism and clinical positioning familiar to MS specialists.
Its principal disadvantages are the need for infusion-center visits, premedication and monitoring. KESIMPTA avoids those operational requirements through self-administration at home.
How have BRIUMVI sales developed since launch?
BRIUMVI moved from launch-stage revenue to a substantial commercial product within its first year. TG Therapeutics reported approximately $362.6 million in net product sales for 2023, its first full year of commercialization. The result exceeded the company's initial launch expectations and made BRIUMVI the company's dominant revenue source.
TG reported approximately $100 million of BRIUMVI net product sales in the first quarter of 2024, indicating that the product entered 2024 at an annualized revenue level of roughly $400 million before subsequent quarterly growth. The trajectory reflected continued patient starts, favorable reimbursement execution and increased account penetration.
| Period | BRIUMVI commercial status | Reported or indicated sales level |
|---|---|---|
| December 2022 | FDA approval | No meaningful commercial period |
| 2023 | First full launch year | Approximately $362.6 million |
| Q1 2024 | Continued expansion | Approximately $100 million |
| 2024 run rate | Based on Q1 performance | Approximately $400 million before later growth |
The quality of the revenue is important. BRIUMVI is sold through the buy-and-bill channel, so reported net product sales reflect gross sales less rebates, discounts, chargebacks and other deductions. Revenue growth does not translate directly into patient growth because the net price per treated patient varies by payer and channel.
What is driving BRIUMVI revenue growth?
Physician adoption and patient conversion
TG's first commercial task was to establish BRIUMVI as a credible alternative to OCREVUS. The drug's one-hour maintenance infusion is a direct selling point for practices that face infusion-chair constraints. Shorter chair time can improve clinic throughput and reduce the operational burden associated with high-volume infusion products.
Patient conversion can occur from several groups:
- Newly diagnosed patients starting high-efficacy therapy.
- Patients switching from other anti-CD20 antibodies.
- Patients moving from lower-efficacy injectable or oral therapies.
- Patients seeking an infusion schedule with fewer or shorter visits.
The third group has commercial value but may involve greater payer-management friction because insurers often require step therapy or prior authorization.
Reimbursement and contracting
BRIUMVI's performance depends on commercial insurers, Medicare and Medicaid coverage. In the physician-administered market, reimbursement is influenced by the product's average sales price, payer policies, site of care and provider economics.
TG has emphasized rapid market access and broad payer coverage as launch priorities. A favorable reimbursement profile can support adoption even when clinical differentiation is modest. A weak reimbursement position would increase the cost of switching from established anti-CD20 therapies.
Infusion-center economics
BRIUMVI's shorter infusion time creates a provider-level economic argument. Infusion centers can treat more patients with the same chair capacity, which matters in large neurology practices and hospital outpatient departments.
The commercial effect is strongest where infusion capacity is constrained. It is weaker in practices that already have established OCREVUS workflows or where patients prefer home administration.
How does BRIUMVI compare with OCREVUS and KESIMPTA?
| Factor | BRIUMVI | OCREVUS | KESIMPTA |
|---|---|---|---|
| Company | TG Therapeutics | Roche/Genentech | Novartis |
| Target | CD20-positive B cells | CD20-positive B cells | CD20-positive B cells |
| Administration | Intravenous | Intravenous | Subcutaneous |
| Maintenance frequency | Every 24 weeks | Every 24 weeks | Monthly after loading |
| Key convenience point | Short maintenance infusion | Established infusion franchise | Home administration |
| Commercial maturity | Newer entrant | Category leader | Established growth product |
| Main switching argument | Short infusion and price | Clinical familiarity and scale | Avoids infusion center |
| Main commercial risk | Smaller sales infrastructure | Less time-efficient infusion | Self-administration preference |
OCREVUS has the largest installed base and substantial physician familiarity. Roche also has a broad MS commercial infrastructure and long experience supporting infusion therapies.
KESIMPTA attacks the market from a different direction. It is attractive to patients who prioritize home dosing and want to avoid infusion-center administration. BRIUMVI is therefore positioned between two established models: OCREVUS's infusion leadership and KESIMPTA's home-use convenience.
Clinical-trial comparisons across separate studies do not establish superiority. BRIUMVI's commercial differentiation depends more on administration time, access, provider economics and patient preference than on a clearly demonstrated efficacy advantage.
What is the FDA regulatory and exclusivity status of BRIUMVI?
BRIUMVI received FDA approval under biologics regulation as BLA 761238 on Dec. 28, 2022. It is a licensed biologic reference product rather than a small-molecule drug.
The Biologics Price Competition and Innovation Act provides 12 years of reference-product exclusivity from the date of first licensure, subject to statutory rules and any applicable pediatric extension. On that basis, the core U.S. biologic exclusivity period runs to Dec. 28, 2034, before considering any six-month pediatric extension.
| Regulatory protection | Date or status |
|---|---|
| FDA approval | Dec. 28, 2022 |
| Reference biologic exclusivity | Generally through Dec. 28, 2034 |
| Potential pediatric extension | Could add six months if statutory conditions are met |
| Small-molecule exclusivity | Not applicable |
| Biosimilar pathway | 351(k) pathway applies |
| Orange Book listing | Not the primary biologic patent reference |
| Purple Book status | Relevant FDA reference-product database |
The FDA Orange Book principally covers approved small-molecule drugs and does not function as the primary patent-listing system for licensed biologics. BRIUMVI's biologic exclusivity and patent position must therefore be evaluated through the Purple Book, FDA approval records, USPTO records and litigation databases.
What patents protect BRIUMVI?
BRIUMVI's protection is based on a combination of biologic exclusivity, antibody-related patent rights, formulation and manufacturing rights, and potential method-of-use claims. Unlike a conventional tablet, an anti-CD20 antibody may have multiple relevant patent families covering:
- The antibody molecule and binding characteristics.
- Glycoengineering or Fc-related properties.
- Methods for treating multiple sclerosis.
- Dosing schedules and infusion regimens.
- Pharmaceutical compositions.
- Cell lines, purification and manufacturing processes.
Patent protection cannot be reduced to the 12-year biologic exclusivity period. Patent terms depend on priority dates, patent-term adjustment, patent-term extension, terminal disclaimers and claim scope. The commercial significance of a patent also depends on whether a biosimilar applicant can design around it or challenge it under the BPCIA process.
As of the public commercial record through mid-2024, BRIUMVI had not generated a major publicly reported U.S. biosimilar patent litigation dispute comparable to the litigation histories of older biologics. That does not eliminate later challenge risk. A biosimilar applicant could initiate a patent exchange and litigation process before commercial launch, subject to the BPCIA framework.
When could BRIUMVI face biosimilar competition?
A biosimilar applicant cannot rely only on the expiration of a single patent. It must account for the statutory biologic exclusivity period, patent litigation, manufacturing readiness and FDA review.
The earliest practical U.S. biosimilar timing is constrained by the Dec. 28, 2034 reference-product exclusivity date, assuming no pediatric extension and no separate legal development. Commercial entry could occur later if patent disputes, settlement agreements or regulatory delays extend the timeline.
The likely sequence is:
| Stage | Expected relevance |
|---|---|
| Reference-product exclusivity | Blocks biosimilar approval for the statutory period |
| Patent-information exchange | May begin before commercial launch |
| Patent litigation | Determines whether listed or asserted claims block entry |
| FDA biosimilar review | Requires analytical and clinical comparability |
| Manufacturing scale-up | A major barrier for complex antibodies |
| Commercial launch | Depends on settlement, court outcome and interchangeability strategy |
The risk profile is lower in the near term than for older anti-CD20 products because BRIUMVI is a recent biologic. The larger strategic risk before biosimilar entry is competitive erosion from OCREVUS and KESIMPTA, not immediate loss of exclusivity.
Which companies are challenging BRIUMVI commercially?
No single competitor needs to challenge BRIUMVI through litigation to limit its sales. The main competitive pressure comes from established MS products.
Roche and Genentech
OCREVUS has a large installed base and a strong physician network. Roche can defend its position through clinical familiarity, patient support and payer contracting. Its principal vulnerability is infusion duration and treatment-center capacity.
Novartis
KESIMPTA competes through self-administration and monthly dosing. Its commercial strength is greatest among patients who want to avoid infusion centers. Novartis also has an established MS franchise and broad payer experience.
Biogen and other MS companies
TYSABRI, VUMERITY, TECFIDERA, PLEGRIDY and other therapies retain roles across different disease-severity and patient-preference segments. They may not be direct substitutes for BRIUMVI in every patient, but they compete for treatment starts and switches.
Rituximab
Rituximab is used off-label in MS in some markets and practices. Its lower acquisition cost can create pricing pressure, although off-label use lacks the same FDA-approved MS indication and may encounter reimbursement or institutional restrictions.
What generic launch risks exist for BRIUMVI?
Traditional generic substitution is not the primary threat because BRIUMVI is a biologic. The relevant threat is a biosimilar or interchangeable biosimilar.
Near-term launch risks are limited by:
- Twelve-year reference-product exclusivity.
- Complexity of antibody manufacturing.
- Need for substantial analytical comparability.
- Provider and payer switching requirements.
- TG's ability to assert composition, use and manufacturing patents.
- The need for a biosimilar sponsor to build commercial and distribution infrastructure.
Longer-term risks increase when the product has a large and predictable patient base. BRIUMVI's growth could make it more attractive to biosimilar developers, particularly if anti-CD20 biosimilar manufacturing platforms are already established for rituximab and other antibodies.
How strong is the BRIUMVI commercial and patent estate?
BRIUMVI's commercial position is stronger than its size alone suggests because the product reached substantial revenue rapidly and operates in a high-value biologic category. Its strengths are:
- Fast uptake after approval.
- A differentiated infusion-time proposition.
- Twice-yearly maintenance treatment.
- A large and established MS market.
- Long statutory biologic exclusivity.
- Provider economics that favor shorter infusion sessions.
The weaknesses are equally clear:
- TG Therapeutics has a narrower commercial portfolio than Roche or Novartis.
- BRIUMVI lacks a home-administration option.
- OCREVUS has entrenched prescribing habits.
- KESIMPTA offers a different convenience model.
- Revenue concentration in one product increases corporate exposure.
- Long-term patent strength depends on claim scope and enforceability, not simply on the existence of patents.
What is the revenue exposure for TG Therapeutics?
BRIUMVI is TG Therapeutics' core commercial asset. The company's financial trajectory is therefore highly sensitive to BRIUMVI prescription growth, gross-to-net deductions and operating expenses.
A simplified revenue framework is:
| Variable | Effect on TG Therapeutics |
|---|---|
| New patient starts | Direct volume growth |
| Switching from OCREVUS or other therapies | Accelerates share capture |
| Net price after discounts | Determines revenue quality |
| Infusion-center access | Limits or expands treatment capacity |
| Payer restrictions | Affects conversion and persistence |
| Sales-force productivity | Determines cost of growth |
| Manufacturing scale | Affects supply and gross margin |
| Competitive pricing | Can reduce net revenue per patient |
The company can generate operating leverage if BRIUMVI sales continue to expand faster than commercial and research spending. That makes the product's first several full years important for cash generation and valuation. Conversely, slower patient additions or heavier rebates would reduce the speed at which TG Therapeutics converts revenue into sustainable profitability.
What is the outlook for BRIUMVI through the end of the decade?
BRIUMVI's most likely growth path is continued share capture within the infusion-based anti-CD20 segment, followed by slower expansion as OCREVUS and KESIMPTA defend their installed bases.
The strongest growth period should occur while:
- Awareness among MS specialists is still increasing.
- Infusion centers value shorter chair time.
- Payers permit switching without excessive restrictions.
- TG expands community neurology access.
- BRIUMVI maintains a meaningful net-price advantage.
The principal inflection points are market share stabilization, payer contracting, evidence from longer-term use and any future label expansion. The product does not need to displace OCREVUS to become a major asset. A durable position as the leading short-infusion alternative could support substantial revenue through the 2030s, well before biosimilar entry becomes the central issue.
Key Takeaways
- BRIUMVI is TG Therapeutics' approved anti-CD20 biologic for relapsing forms of multiple sclerosis.
- FDA approval occurred on Dec. 28, 2022, under BLA 761238.
- The product generated approximately $362.6 million in 2023 net product sales.
- Early 2024 performance indicated an annualized revenue base above $400 million.
- Its main commercial differentiation is a one-hour maintenance infusion every 24 weeks.
- OCREVUS is the primary infusion competitor; KESIMPTA is the leading home-administration competitor.
- The statutory U.S. biologic exclusivity period generally extends to Dec. 28, 2034, before any pediatric extension.
- BRIUMVI does not rely on traditional Orange Book protection because it is a licensed biologic.
- No major publicly reported U.S. biosimilar litigation had affected BRIUMVI through mid-2024.
- TG Therapeutics has substantial revenue concentration in BRIUMVI, making market-share execution and payer access central to valuation.
FAQs About BRIUMVI Market Dynamics and Financial Outlook
Is BRIUMVI a biosimilar or an original biologic?
BRIUMVI is an original FDA-licensed biologic reference product. It is not a biosimilar. Future competitors would need to pursue the FDA's 351(k) biosimilar pathway.
Does BRIUMVI have an Orange Book patent listing?
The Orange Book is not the primary FDA patent database for licensed biologics. BRIUMVI's relevant regulatory and patent information is evaluated through the Purple Book, FDA records and USPTO sources.
What is the biggest threat to BRIUMVI sales?
The largest near- and medium-term threat is commercial competition from OCREVUS and KESIMPTA, rather than generic substitution. OCREVUS has an established infusion base, while KESIMPTA offers home administration.
Can BRIUMVI be administered at home?
BRIUMVI is administered by intravenous infusion under appropriate clinical supervision. Its current value proposition is a short infusion-center visit, not home self-administration.
Why is infusion duration important for BRIUMVI economics?
A shorter infusion can increase infusion-center capacity, reduce chair-time costs and improve provider throughput. Those factors can influence neurologist prescribing even when competing products have similar broad treatment positioning.
References
- U.S. Food and Drug Administration. (2022). FDA approves new drug to treat multiple sclerosis.
- U.S. Food and Drug Administration. (2022). BRIUMVI prescribing information.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- TG Therapeutics, Inc. (2024). 2023 annual report on Form 10-K.
- TG Therapeutics, Inc. (2024). First-quarter 2024 financial results and business update.
- Roche. (2024). OCREVUS prescribing information.
- Novartis Pharmaceuticals Corporation. (2024). KESIMPTA prescribing information.
- U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, ยง7002.
More… ↓
